GLP-1 medications usually have a mild to moderate risk of developing side effects
GLP-1 therapies are reshaping obesity, diabetes, and even cardiovascular care Demand has outpaced global manufacturing capacity A grey market has emerged and regulators are now stepping in to contain it Patients want affordable, available treatment
If youve found yourself asking, What is the best female libido enhancer
Prior to the popularity of the GLP-1 agonist drugs, other substances were used for medication-assisted weight loss, including controlled substances
The promise of such efficacy has made Tirzepatide, in all its forms, a game-changer for individuals seeking a medical solution to achieve healthier body weight
GLP-1 Pipeline Update: May 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior, Pipeline DISCLAIMER The drug pipeline is fluid
